590 material Form 8-K filings that 521 companies we cover made with the SEC in October 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Huntington Bancshares reported third-quarter 2024 net income of $517 million, or $0.33 per share, up $0.03 from the prior quarter and down $0.02 from the year-ago quarter. Total revenue on a fully taxable-equivalent basis rose 4% from the prior quarter to $1,887 million but was flat year over year, and management said it expects accelerated loan growth to continue in the fourth quarter.
Net income $517 million, or $0.33 per share, versus $474 million, or $0.30, in the second quarter and $547 million, or $0.35, a year ago
Net interest income rose $39 million, or 3%, from the prior quarter but fell $17 million, or 1%, from the year-ago quarter
Noninterest income rose $32 million, or 7%, from the prior quarter to $523 million; nonperforming assets were $784 million, or 0.62% of loans and other real estate
Common Equity Tier 1 ratio was 10.4% at September 30, 2024, estimated and unchanged from the prior quarter; tangible book value per share was $8.65
KeyCorp reported a third-quarter 2024 net loss from continuing operations attributable to common shareholders of $447 million, or $0.47 per diluted share, after $737 million in after-tax charges tied to a securities portfolio repositioning. Excluding those charges, adjusted net income was $290 million, or $0.30 per diluted share, up from $237 million, or $0.25, in the second quarter, though total revenue fell to $695 million from $1.5 billion. The company received an initial $821 million tranche of its Scotiabank strategic investment, and expects the final tranche in the first quarter of 2025, subject to Federal Reserve approval.
Net loss of $447 million, or $0.47 per diluted share, versus net income of $266 million in the third quarter of 2023
Adjusted net income of $290 million, or $0.30 per diluted share, excluding $737 million in after-tax charges
Net interest income rose 7% quarter-over-quarter to $964 million; total revenue (TE) was $695 million versus $1,526 million in the second quarter
Received initial $821 million Scotiabank investment tranche; Common Equity Tier 1 ratio was 10.8%
Snap-on reported third-quarter 2024 results for the quarter ended September 28, 2024. Net sales fell 1.1% to $1,147.0 million, but diluted earnings per share rose 4.2% to $4.70, helped by an operating margin before financial services of 22.0%, up from 21.2%. For shareholders, per-share profit grew even though sales declined, and the company reaffirmed a 22% to 23% full-year 2024 tax rate outlook.
Net sales were $1,147.0 million, down $12.3 million or 1.1% from $1,159.3 million; organic sales fell 1.7%.
Net earnings attributable to Snap-on were $251.1 million, or $4.70 per diluted share, versus $4.51 a year earlier.
Operating margin before financial services was 22.0%, compared with 21.2% last year.
Full-year 2024 effective tax rate is expected to be 22% to 23%; 2024 capital expenditures are projected at about $100 million, with $65.4 million spent in the first nine months.
Elevance Health reported third quarter 2024 operating revenue of $44.7 billion, up 5.3% from a year earlier, but GAAP diluted EPS fell 20.0% to $4.36 and the operating gain fell 19.8% to $1.4 billion. The company cited a timing mismatch between Medicaid rates and the higher acuity of its members, which pushed the benefit expense ratio up 270 basis points to 89.5%. It now expects 2024 GAAP EPS of approximately $26.50 and adjusted EPS of approximately $33.00, and on October 15, 2024 it authorized an $8.0 billion increase to its share repurchase program.
Q3 2024 operating revenue $44.7 billion, up $2.2 billion from the prior year quarter, driven by higher premium yields and CarelonRx product revenue
Q3 2024 GAAP diluted EPS $4.36 versus $5.45 a year earlier; adjusted diluted EPS $8.37 versus $8.99
Medical membership fell 3.3% year over year to 45,760 thousand, with Medicaid down 19.0% to 8,926 thousand
Board authorized an $8.0 billion increase to the share repurchase program on October 15, 2024; quarterly dividend of $1.63 per share declared
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.